Starton Therapeutics, Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, and Healthwell Acquisition Corp. I (Nasdaq: HWEL) (“Healthwell”), a special purpose acquisition company, announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which, among other things, HWEL Holdings Corp., a newly formed wholly-owned subsidiary of Healthwell (“Pubco”), has agreed to acquire Starton and become a publicly traded company (the “Transaction”).
Read the full article: Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments //
Source: https://www.businesswire.com/news/home/20230425006209/en/Starton-Therapeutics-Inc.-and-Healthwell-Acquisition-Corp.-I-to-Combine-and-Create-Publicly-Traded-Leader-in-Proprietary-Continuous-Delivery-Technology-for-Cancer-Treatments